Glucose 2.5g/10ml / Phenol 250mg/10ml / Glycerol 2.5ml/10ml solution for injection ampoules
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Glucose + Phenol + Glycerol on the MHRA register
Glucose 2.5g/10ml / Phenol 250mg/10ml / Glycerol 2.5ml/10ml solution for injection ampoules
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · 1969–2025
Showing the 50 most relevant studies, sorted by most relevant.
Corneliu Tanase, Sanda Coşarcă, Daniela-Lucia Muntean
Molecules, 2019
- Anti-Inflammatory Agents
- Anti-Bacterial Agents
- Antineoplastic Agents, Phytogenic
Mathias Klein, Steve Swinnen, J. Thevelein, et al.
Environmental microbiology, 2017
Rendine M, Marino M, Martini D, et al.
2025
- Adipocytes
- Obesity
- Glucose
Purpose of reviewThis systematic review aims to elucidate the effects of (poly)phenols (PPs) on mature 3T3-L1 adipocytes via the regulation of lipid and glucose metabolism.Recent findingsPPs can modulate glucose uptake, reduce intracellular lipid content and enhance lipolytic activity in mature 3T3-L1 adipocytes. These effects are mediated through changes at both gene expression level (e.g. Ppara and Sirt1) and protein level (e.g. activation of AMPK and adiponectin levels). However, there is no consensus on the concentrations at which PPs exert their anti-lipogenic activity, and it remains unclear whether different PPs activate distinct molecular pathways. PPs are a diverse group of plant-derived secondary metabolites with recognized anti-obesogenic potential. While their inhibitory effects on adipogenesis are well established, their role in modulating lipid metabolism in fully differentiated adipocytes remains less well understood. Emerging evidence from studies on mature 3T3-L1 adipocytes indicates that PPs can influence key metabolic processes, including lipid storage and mobilization. These findings highlight the potential of PPs as modulators of adipose tissue metabolism, while also emphasizing the need for translational research to clarify their mechanisms of action and therapeutic efficacy in vivo.
Abstract licence: CC BY
Gautam Gaur, Michael G. Gänzle
Current Research in Food Science, 2023
Fabrizio Fontana, Gaia Giannitti, Sara Marchesi, et al.
International Journal of Biological Sciences, 2024
- Glucose
- Neoplasms
- Signal Transduction
Lena Vogt, Florian Ruther, Sahar Salehi, et al.
Advanced Healthcare Materials, 2021
- Decanoates
- Glycerol
- Biocompatible Materials
Yongping Liang, Meng Li, Yutong Yang, et al.
ACS nano, 2022
Bianca R. Albuquerque, Sandrina A. Heleno, M. Beatriz P.P. Oliveira, et al.
Food & Function, 2020
- Industry
- Anti-Infective Agents
- Anti-Inflammatory Agents
E. Ferrannini, S. Baldi, S. Frascerra, et al.
Diabetes, 2016
Emilio Gil‐Martín, Tamara Y. Forbes‐Hernández, Alejandro Romero, et al.
Food Chemistry, 2021
- Phenols
- Polyphenols
- Antioxidants
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.